Vav 3 Oncogene (VAV3) Antibody

Documentos del producto

Especificaciones del producto

Primary Antibodies

Target: Vav 3 Oncogene (VAV3)
Immunogen: VAV3 (His183-Glu380)

Rabbit

Human

WB: 1-5 µg/ml, IHC: 5-20 µg/ml, IF/ICC (Predicted): 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.

100 µl

200 µl

1 ml

Liquid

WB, IHC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Shipped within 5-7 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

VAV-3

Antibody anti-VAV3

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Background

VAV3 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) that regulate Rho family GTPases, such as Rac1, RhoA, and Cdc42, to mediate cytoskeletal reorganization, cell migration, and proliferation. VAV3 is expressed in multiple tissues, including the brain, endothelial cells, and immune cells, where it functions in signaling pathways downstream of receptor tyrosine kinases (RTKs), integrins, and immune receptors. It is involved in processes like angiogenesis, neuronal development, and immune cell activation. Dysregulation of VAV3 is associated with cancer, where it promotes tumor cell migration, metastasis, and survival through Rac1 activation and integrin signaling. VAV3 also plays a role in immune responses, including T-cell activation and macrophage function. Knockout studies demonstrate impaired angiogenesis, defective immune cell migration, and reduced tumor metastasis, highlighting its essential role in cytoskeletal regulation, cell signaling, and tumor progression.